Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thymorell is a biological medicinal product containing thymus extract, developed and marketed by Sanorell Pharma. It is primarily utilized in complementary medicine and supportive oncology to modulate and strengthen the immune system. The preparation consists of a complex mixture of peptides and proteins derived from the thymus gland, which are intended to stimulate the maturation, differentiation, and proliferation of T-lymphocytes. In Germany, it is frequently used as an adjuvant treatment for patients with malignant tumors or chronic recurrent infections to improve immune competence and overall quality of life. The drug is typically administered via parenteral routes, such as intramuscular or subcutaneous injection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Thymorell.